Literature DB >> 25842732

Anti-tumor effect of the extract from qingyihuaji formula on pancreatic cancer by down-regulating Notch-4 and Jagged-1.

Yanli Xu, Feiye Zhu, Shan Xu, Luming Liu.   

Abstract

OBJECTIVE: To investigate, in terms of Notch signaling pathway, the effect on pancreatic cancer of the extract of an anti-tumor prescription--Qingyi-huaji formula (QYHJ)--from Traditional Chinese Medicine (TCM).
METHODS: Nude mice were implanted subcutaneously with human pancreatic cancer cell line SW1990 and then randomly divided into four groups: Control, QYHJ extract, Gemcitabine, and Combination of QYHJ extract and gemcitabine. Treatments were given for 21 days and tumor growth was evaluated simultaneously. Then, expression of Notch receptors (Notch-1, Notch-2, Notch-3, and Notch-4) and their Jagged ligands (Jagged-1 and Jagged-2) in dissected tumor tissue were detected by real-time quantitative reverse transcription-polymerase chain reaction and Western blot. Finally, immunohistochemistry was performed to detect CD133, a marker of pancreatic cancer stem cells (CSCs), to evaluate the impact of QYHJ extract on pancreatic CSCs.
RESULTS: QYHJ extract treatment effectively inhibited the tumor growth in nude mice. The expression of both Notch-4 and Jagged-1 were decreased significantly in QYHJ treatment groups (P < 0.05), while gemcitabine alone had no significant effect in down-regulating Jagged-1 (P > 0.05). No significant difference was observed in the ex- pression of Notch-1, Notch-2, Notch-3, and Jagged-2 between three treatment groups and control group (P > 0.05). Moreover, immunohistochemical analysis showed that the number of CD133 positive cells was significantly reduced by QYHJ treatment (P < 0.05), and the combined treatment was more effective than gemcitabine alone (P < 0.05).
CONCLUSION: The role of the extract in pancreatic cancer treatment was associated with down-regulation of Notch-4 and Jagged-1 in Notch signaling pathway. The extract could enhance the antitumor activity of gemcitabine and was more effective than gemcitabine in regulating Notch signaling pathway to some extent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25842732     DOI: 10.1016/s0254-6272(15)30012-1

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  7 in total

1.  Babaodan Capsule () combined with Qingyi Huaji Formula () in advanced pancreatic cancer-a feasibility study.

Authors:  Li-Bin Song; Song Gao; Ai-Qin Zhang; Xiang Qian; Lu-Ming Liu
Journal:  Chin J Integr Med       Date:  2017-05-27       Impact factor: 1.978

2.  Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose?

Authors:  Meng Li; Miao-Miao Wang; Xiu-Wei Guo; Chao-Yong Wu; Dao-Rui Li; Xing Zhang; Pei-Tong Zhang
Journal:  Chin J Integr Med       Date:  2017-10-24       Impact factor: 1.978

3.  Bone marrow mesenchymal stem cells promote prostate cancer cell stemness via cell-cell contact to activate the Jagged1/Notch1 pathway.

Authors:  Ji-Wen Cheng; Li-Xia Duan; Yang Yu; Pu Wang; Jia-le Feng; Guan-Zheng Feng; Yan Liu
Journal:  Cell Biosci       Date:  2021-05-17       Impact factor: 7.133

Review 4.  Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

Review 5.  Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.

Authors:  Qingxi Yue; Guogang Gao; Gangyong Zou; Haiqing Yu; Xi Zheng
Journal:  Biomed Res Int       Date:  2017-01-23       Impact factor: 3.411

6.  Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals.

Authors:  Peng Chen; Meiying Wang; Cuiping Wang
Journal:  Biosci Rep       Date:  2019-06-18       Impact factor: 3.840

7.  Expression of Notch receptors and their ligands in pancreatic ductal adenocarcinoma.

Authors:  Hai-Yan Song; Ying Wang; Hong Lan; Yu-Xiang Zhang
Journal:  Exp Ther Med       Date:  2018-05-16       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.